Why the study?
Does dalteparin reduce all-cause mortality in patients with solid tumors and acute venous thromboembolism compared to coumarin derivatives?
Does dalteparin reduce all-cause mortality in patients with solid tumors and acute venous thromboembolism compared to coumarin derivatives?
Dalteparin is associated with improved survival relative to coumarin derivatives in patients with solid tumors and acute VTE who do not have metastatic disease.
No takes yet. Share an insight, caveat, or question.
Supports dalteparin over oral anticoagulants to reduce mortality in non-metastatic cancer VTE; extends RCT evidence for LMWH in this subgroup.
Lee et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: